Christine Zedelmayer Sells 9,821 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 9,821 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $2.70, for a total value of $26,516.70. Following the sale, the chief operating officer directly owned 62,586 shares of the company’s stock, valued at $168,982.20. The trade was a 13.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The stock was sold at an average price of $2.80, for a total value of $240,833.60.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Stock Performance

Equillium stock traded up $0.06 during mid-day trading on Friday, reaching $2.90. 853,917 shares of the company were exchanged, compared to its average volume of 480,896. Equillium, Inc. has a twelve month low of $0.27 and a twelve month high of $3.10. The firm’s 50-day simple moving average is $2.09 and its two-hundred day simple moving average is $1.63. The firm has a market cap of $183.37 million, a PE ratio of -9.06 and a beta of 1.67.

Equillium (NASDAQ:EQ) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). As a group, equities research analysts anticipate that Equillium, Inc. will post -0.24 EPS for the current year.

Analysts Set New Price Targets

EQ has been the subject of several recent analyst reports. Raymond James Financial reissued a “strong-buy” rating and issued a $7.00 price target on shares of Equillium in a report on Thursday. Leerink Partners raised Equillium from a “market perform” rating to an “outperform” rating and raised their price target for the company from $1.00 to $6.00 in a report on Thursday. Zacks Research raised Equillium to a “hold” rating in a research note on Thursday, February 26th. Cantor Fitzgerald began coverage on Equillium in a research note on Tuesday, April 7th. They issued an “overweight” rating and a $10.00 price objective for the company. Finally, Stifel Nicolaus set a $5.00 price objective on Equillium in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.57.

Institutional Investors Weigh In On Equillium

Several hedge funds have recently made changes to their positions in EQ. Dimensional Fund Advisors LP acquired a new position in shares of Equillium during the first quarter worth about $31,000. Virtu Financial LLC lifted its stake in shares of Equillium by 133.4% during the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after purchasing an additional 13,591 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Equillium during the third quarter worth about $35,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Equillium during the first quarter worth about $100,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Equillium during the third quarter worth about $99,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

Equillium News Roundup

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.